Re: GYN: Menostar

From: Garry E. Siegel, M.D. (garrys@mindspring.com)
Wed Sep 29 17:08:58 2004


Thanks for the input. Joanne, would love to see anything you find.

Garry

At Wed, 29 Sep 2004, Charlie Chambers wrote: >
>--Apple-Mail-1-64545382
>Content-Transfer-Encoding: quoted-printable
>Content-Type: text/plain;
> charset=ISO-8859-1;
> delsp=yes;
> format=flowed
>
>Two years doesn't seem long enough to feel confident about hyperplasia
>incidents. Plus, no meaningful fracture data. Would be a lot more
>helpful if these companies that are putting forth new meds for osteo to
>get some fracture data instead of quick BMD data.
>
>On Sep 29, 2004, at 11:24 AM, RModugno@aol.com wrote:
>
>> In a message dated 9/29/04 12:14:35 AM Eastern Daylight Time,
>> zbnewton@bellsouth.net writes:
>> The limiting issue is the outlier who develops an endometrial
>> malignancy
>> while under such a regimen that has not been standardized  The
>> liability
>> issue will devastate the prescriber, regardless of benefit/risk
>> arguments.
>>
>> If the uterus is there with estrogen therapy, progesterone/progestin
>> additive on a standardized basis is obligatory. By today's standards,
>> p-therapy every 4 or 6 months for the individual who does develop
>> endometrial carcinoma will come back to bite you.
>>
>> Zach Newton
>> Z. B. Newton, III, M.D.
>> Atlanta/ Gyn
>> Zach, this comes from Berlex:
>>  
>>
>> "Menostar is a fundamentally new approach to post-menopausal
>> osteoporosis prevention. In a two-year clinical study, Menostar, with
>> a very low dose of estrogen, did not increase the risk of endometrial
>> hyperplasia among women with a uterus. Therefore, this patch does not
>> require a daily or monthly concomitant progestin," said Marie Foegh,
>> M.D., Vice President, Medical Affairs for Berlex Laboratories. "Until
>> now, we in the medical community never knew such small amounts of
>> estrogen could help maintain bone health. With Menostar, we can return
>> a woman's estrogen to the lowest level proven to prevent bone loss."
>>
>> I would suggest, therefore, that a 4 to 6 month progesterone
>> "challenge' is acceptable therapy.
>>
>> Robert Modugno Md MBA FACOG
>>
>> Marietta, GA
>>
>> http://www.novaobgyn.yourmd.com
>>
>>  
>>
>************************************************************************
>****
>************************************************************************

>
>--
>Charlie Chambers
>Hood River, OR USA
>cchamber@alumni.rice.edu
>
>"...not because I regard fishing as being so terribly
>important but because I suspect that so many of the other
>concerns of men are equally unimportant-and not nearly
>so much fun."
> John Voelker
>************************************************************************
>*****
>************************************************************************

>
>--Apple-Mail-1-64545382
>Content-Transfer-Encoding: quoted-printable
>Content-Type: text/enriched;
> charset=ISO-8859-1
>
>Two years doesn't seem long enough to feel confident about hyperplasia
>incidents. Plus, no meaningful fracture data. Would be a lot more
>helpful if these companies that are putting forth new meds for osteo
>to get some fracture data instead of quick BMD data.
>
>On Sep 29, 2004, at 11:24 AM, RModugno@aol.com wrote:
>
><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>In a message
>dated 9/29/04 12:14:35 AM Eastern Daylight Time,
>zbnewton@bellsouth.net writes:</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>The limiting
>issue is the outlier who develops an endometrial malignancy</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>while under
>such a regimen that has not been standardized  The liability</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>issue will
>devastate the prescriber, regardless of benefit/risk arguments.</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>If the uterus
>is there with estrogen therapy, progesterone/progestin</x-tad-smaller></smaller></fontfamily></excerpt><e cerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>additive on a
>standardized basis is obligatory. By today's standards,</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>p-therapy
>every 4 or 6 months for the individual who does develop</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>endometrial
>carcinoma will come back to bite you.</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>Zach Newton</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>Z. B. Newton,
>III, M.D.</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>Atlanta/ Gyn</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>Zach, this
>comes from Berlex:</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
>><fontfamily><param>Arial</param><smaller><x-tad-smaller> </x-tad-smalle ></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>"Menostar is a
>fundamentally new approach to post-menopausal osteoporosis prevention.
>In a two-year clinical study, Menostar, with a very low dose of
>estrogen, did not increase the risk of endometrial hyperplasia among
>women with a uterus. Therefore, this patch does not require a daily or
>monthly concomitant progestin," said Marie Foegh, M.D., Vice
>President, Medical Affairs for Berlex Laboratories. "Until now, we in
>the medical community never knew such small amounts of estrogen could
>help maintain bone health. With Menostar, we can return a woman's
>estrogen to the lowest level proven to prevent bone loss."</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>I would
>suggest, therefore, that a 4 to 6 month progesterone "challenge' is
>acceptable therapy.</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>Robert Modugno
>Md MBA FACOG</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
><fontfamily><param>Arial</param><smaller><x-tad-smaller>Marietta, GA</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
>><fontfamily><param>Arial</param><smaller><x-tad-smaller>http://www.novaobgyn.you md.com</x-tad-smaller></smaller></fontfamily></excerpt><excerpt>
>
>><fontfamily><param>Arial</param><smaller><x-tad-smaller> </x-tad-smalle ></smaller></fontfamily></excerpt><excerpt>
>
>></excerpt>*************************************************************** ************
>
></excerpt>*************************************************************** ************

>Charlie Chambers
>
>Hood River, OR USA
>
>cchamber@alumni.rice.edu
>
>"...not because I regard fishing as being so terribly
>
>important but because I suspect that so many of the other
>
>concerns of men are equally unimportant-and not nearly
>
>so much fun."
>
> John Voelker
>
>>************************************************************************* ***
>
>************************************************************************* ***

>
>--Apple-Mail-1-64545382--
>

--
Garry E. Siegel, M.D.
Private Practice
Roswell, GA




use when must restrict search to only the ob-gyn-l forum...
Enter search keywords:
Returns per screen: Require all keywords:

Return to  OB-GYN-L Mail a New Message to the Forum: ob-gyn-l@obgyn.net
Forum Administrator: geffrey.klein@obgyn.net
Report Technical Problems: webmaster@obgyn.net
Last Updated: Wed Jul 2 04:37:54 2008

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.